Recommendations for liver transplantation for hepatocellular carcinoma: An international consensus conference report

The Lancet Oncology

Volumn 13, Issue 1, 2012, Pages

  Clavien, Pierre Alain ^a   Lesurtel, Mickael ^a   Bossuyt, Patrick MM ^b   Gores, Gregory J ^c   Langer, Bernard ^d   Perrier, Arnaud ^e  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; LICARTIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; SORAFENIB; UNCLASSIFIED DRUG;

CADAVER DONOR; CANCER STAGING; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS DEVELOPMENT; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER TRANSPLANTATION; LIVING DONOR; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN DONOR; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SWITZERLAND; UNSPECIFIED SIDE EFFECT;

CARCINOMA, HEPATOCELLULAR; EVIDENCE-BASED MEDICINE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOADJUVANT THERAPY; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; TISSUE DONORS; TREATMENT OUTCOME; WAITING LISTS;

EID: 84855314307     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70175-9     Document Type: Review

References (104)

1. Results European Liver Transplant Registry, (accessed Jan 1, 2011). http://www.eltr.org/spip.php?rubrique37.
2. OPTN/SRTR Annual Report Organ Procurement and Transplantation Network, (accessed Jan 1, 2011). http://www.ustransplant.org/annual_reports.
3. Grundahl J The Danish consensus conference model. Public participation in science: the role of consensus conferences in Europe 1995, Science Museum, London. S. Joss, J. Durant (Eds.).
4. Levels of evidence (March 2009) Oxford Centre for Evidence-based Medicine, (accessed Nov 1, 2010). http://www.cebm.net/index.aspx?o=1025.
5. Lesurtel M, Clavien PA 2010 international consensus conference on liver transplantation for hepatocellular carcinoma: texts of experts. Liver Transpl 2011, 17(suppl 2):S1-S5.
6. Samuel D, Colombo M, El-Serag H, Sobesky R, Heaton N Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma. Liver Transpl 2011, 17(suppl 2):S6-13.
7. Müllhaupt B, Durand F, Roskams T, Dutkowski P, Heim M Is tumor biopsy necessary?. Liver Transpl 2011, 17(suppl 2):S14-S25.
8. Olthoff KM, Forner A, Hübscher S, Fung J What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation?. Liver Transpl 2011, 17(suppl 2):S26-S33.
9. Lee JM, Trevisani F, Vilgrain V, Wald C Imaging diagnosis and staging of hepatocellular carcinoma. Liver Transpl 2011, 17(suppl 2):S34-S43.
10. Mazzaferro V, Bhoori S, Sposito C, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 2011, 17(suppl 2):S44-S57.
11. Germani G, Gurusamy K, Garcovich M, et al. Which matters most: Number of tumors, size of the largest tumor, or total tumor volume?. Liver Transpl 2011, 17(suppl 2):S58-S66.
12. Llovet JM, Paradis V, Kudo M, Zucman-Rossi J Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. Liver Transpl 2011, 17(suppl 2):S67-S71.
13. Gouw AS, Balabaud C, Kusano H, Todo S, Ichida T, Kojiro M Markers for microvascular invasion in hepatocellular carcinoma: where do we stand?. Liver Transpl 2011, 17(suppl 2):S72-S80.
14. Prasad KR, Young RS, Burra P, et al. Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement. Liver Transpl 2011, 17(suppl 2):S81-S89.
15. Lerut J, Mergental H, Kahn D, et al. Place of liver transplantation in the treatment of hepatocellular carcinoma in the normal liver. Liver Transpl 2011, 17(suppl 2):S90-S97.
16. Majno P, Lencioni R, Mornex F, Girard N, Poon RT, Cherqui D Is the treatment of hepatocellular carcinoma on the waiting list necessary?. Liver Transpl 2011, 17(suppl 2):S98-108.
17. Yao FY, Breitenstein S, Broelsch CE, Dufour JF, Sherman M Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma?. Liver Transpl 2011, 17(suppl 2):S109-S116.
18. Kneteman N, Livraghi T, Madoff D, de Santibañez E, Kew M Tools for monitoring patients with hepatocellular carcinoma on the waiting list and after liver transplantation. Liver Transpl 2011, 17(suppl 2):S117-S127.
19. Pomfret EA, Lodge JP, Villamil FG, Siegler M Should we use living donor grafts for patients with hepatocellular carcinoma? Ethical considerations. Liver Transpl 2011, 17(suppl 2):S128-S132.
20. Grant D, Fisher RA, Abecassis M, McCaughan G, Wright L, Fan ST Should the liver transplant criteria for hepatocellular carcinoma be different for deceased donation and living donation?. Liver Transpl 2011, 17(suppl 2):S133-S138.
21. Greig PD, Geier A, D'Alessandro AM, Campbell M, Wright L Should we perform deceased donor liver transplantation after living donor liver transplantation has failed?. Liver Transpl 2011, 17(suppl 2):S139-S146.
22. Duvoux C, Kiuchi T, Pestalozzi B, Busuttil R, Miksad R What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma?. Liver Transpl 2011, 17(suppl 2):S147-S158.
23. Schlitt HJ, Mornex F, Shaked A, Trotter JF Immunosuppression and hepatocellular carcinoma. Liver Transpl 2011, 17(suppl 2):S159-S161.
24. Davis E, Wiesner R, Valdecasas J, Kita Y, Rossi M, Schwartz M Treatment of recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl 2011, 17(suppl 2):S162-S166.
25. Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008, 336:1106-1110.
26. Chevret S, Trinchet JC, Mathieu D, et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999, 31:133-141.
27. Kudo M, Chung H, Osaki Y Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003, 38:207-215.
28. Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002, 94:1760-1769.
29. Llovet JM, Bru C, Bruix J Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19:329-338.
30. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985, 56:918-928.
31. Omagari K, Honda S, Kadokawa Y, et al. Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma. J Gastroenterol Hepatol 2004, 19:805-811.
32. Tateishi R, Yoshida H, Shiina S, et al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 2005, 54:419-425.
33. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998, 28:751-755.
34. Wildi S, Pestalozzi BC, McCormack L, et al. Critical evaluation of the different staging systems for hepatocellular carcinoma. Br J Surg 2004, 91:400-408.
35. Makuuchi M, Sano K The surgical approach to HCC: our progress and results in Japan. Liver Transpl 2004, 10(suppl 1):46-52.
36. Bilimoria MM, Lauwers GY, Doherty DA, et al. Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch Surg 2001, 136:528-535.
37. Freeman RB, Mithoefer A, Ruthazer R, et al. Optimizing staging for hepatocellular carcinoma before liver transplantation: a retrospective analysis of the UNOS/OPTN database. Liver Transpl 2006, 12:1504-1511.
38. Silva MA, Hegab B, Hyde C, et al. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 2008, 57:1592-1596.
39. Bruix J, Sherman M Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
40. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699.
41. Germani G, Gurusamy K, Garcovich M, et al. What matters: number of tumours, size of largest tumour, or total volume of tumour?. Liver Transpl 2011, published online May 16. 10.1002/lt.22336.
42. Toso C, Trotter J, Wei A, et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2008, 14:1107-1115.
43. Toso C, Asthana S, Bigam DL, et al. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009, 49:832-838.
44. Mazzaferro V, Bhoori S, Sposito C, et al. Milan Criteria in liver transplantation for HCC: an evidence-based analysis on 15 years of experience. Liver Transpl 2011, published online June 21. 10.1002/lt.22365.
45. 21st report Australia and New Zeland Liver Transplant Registry, (accessed Nov 1, 2010). http://www.anzltr.org/thisYear.
46. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001, 33:1394-1403.
47. Yao FY, Xiao L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007, 7:2587-2596.
48. Volk ML, Vijan S, Marrero JA A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant 2008, 8:839-846.
49. Villanueva A, Hoshida Y, Toffanin S, et al. New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 2010, 16:4688-4694.
50. Vibert E, Azoulay D, Hoti E, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2010, 10:129-137.
51. Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008, 85:1726-1732.
52. Ravaioli M, Grazi GL, Piscaglia F, et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008, 8:2547-2557.
53. Lohe F, Angele MK, Rentsch M, et al. Multifocal manifestation does not affect vascular invasion of hepatocellular carcinoma: implications for patient selection in liver transplantation. Clin Transplant 2007, 21:696-701.
54. Parfitt JR, Marotta P, Alghamdi M, et al. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl 2007, 13:543-551.
55. Shah SA, Tan JC, McGilvray ID, et al. Does microvascular invasion affect outcomes after liver transplantation for HCC? A histopathological analysis of 155 consecutive explants. J Gastrointest Surg 2007, 11:464-471.
56. General rules for the clinical and pathological study of primary liver cancer 1997, Liver Cancer Study Group of Japan, Kanehara Co, Tokyo.
57. Kornberg A, Freesmeyer M, Barthel E, et al. 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant 2009, 9:592-600.
58. Fujiki M, Takada Y, Ogura Y, et al. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant 2009, 9:2362-2371.
59. Shirabe K, Itoh S, Yoshizumi T, et al. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol 2007, 95:235-240.
60. Clavien PA, Petrowsky H, DeOliveira ML, et al. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007, 356:1545-1559.
61. Chang CH, Chau GY, Lui WY, et al. Long-term results of hepatic resection for hepatocellular carcinoma originating from the noncirrhotic liver. Arch Surg 2004, 139:320-325.
62. Lang H, Sotiropoulos GC, Domland M, et al. Liver resection for hepatocellular carcinoma in non-cirrhotic liver without underlying viral hepatitis. Br J Surg 2005, 92:198-202.
63. Liu S, Chan KW, Wang B, et al. Fibrolamellar hepatocellular carcinoma. Am J Gastroenterol 2009, 104:2617-2624.
64. Mergental H, Porte RJ Liver transplantation for unresectable hepatocellular carcinoma in patients without liver cirrhosis. Transpl Int 2010, 23:662-667.
65. Houben KW, McCall JL Liver transplantation for hepatocellular carcinoma in patients without underlying liver disease: a systematic review. Liver Transpl Surg 1999, 5:91-95.
66. Lesurtel M, Mullhaupt B, Pestalozzi BC, et al. Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant 2006, 6:2644-2650.
67. Yao FY, Kerlan RK, Hirose R, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008, 48:819-827.
68. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001, 35:421-430.
69. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009, 9:1920-1928.
70. Majno PE, Lencioni R, Mornex F, et al. Is treatment of HCC on the waiting list necessary?. Liver Transpl 2011, 17(suppl 2):S98-108.
71. Martin AP, Goldstein RM, Dempster J, et al. Radiofrequency thermal ablation of hepatocellular carcinoma before liver transplantation-a clinical and histological examination. Clin Transplant 2006, 20:695-705.
72. Pompili M, Mirante VG, Rondinara G, et al. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl 2005, 11:1117-1126.
73. Cronin DC, Millis JM Living donor liver transplantation: the ethics and the practice. Hepatology 2008, 47:11-13.
74. Di Sandro S, Slim AO, Giacomoni A, et al. Living donor liver transplantation for hepatocellular carcinoma: long-term results compared with deceased donor liver transplantation. Transplant Proc 2009, 41:1283-1285.
75. Fisher RA, Kulik LM, Freise CE, et al. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 2007, 7:1601-1608.
76. Hwang S, Lee SG, Joh JW, et al. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. Liver Transpl 2005, 11:1265-1272.
77. Kulik L, Abecassis M Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology 2004, 127(suppl 1):277-282.
78. Lo CM, Fan ST, Liu CL, et al. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg 2007, 94:78-86.
79. Vakili K, Pomposelli JJ, Cheah YL, et al. Living donor liver transplantation for hepatocellular carcinoma: increased recurrence but improved survival. Liver Transpl 2009, 15:1861-1866.
80. Olthoff KM, Merion RM, Ghobrial RM, et al. Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL Consortium. Ann Surg 2005, 242:314-323.
81. Zimmerman MA, Ghobrial RM, Tong MJ, et al. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg 2008, 143:182-188.
82. Hollebecque A, Decaens T, Boleslawski E, et al. Natural history and therapeutic management of recurrent hepatocellular carcinoma after liver transplantation. Gastroenterol Clin Biol 2009, 33:361-369.
83. Roberts JP Tumor surveillance-what can and should be done? Screening for recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2005, 11(suppl 2):45-46.
84. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999, 397:530-534.
85. Soll C, Clavien PA Inhibition of mammalian target of rapamycin: two goals with one shot?. J Hepatol 2011, 54:182-183.
86. Chinnakotla S, Davis GL, Vasani S, et al. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2009, 15:1834-1842.
87. Toso C, Meeberg GA, Bigam DL, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 2007, 83:1162-1168.
88. Toso C, Merani S, Bigam DL, et al. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010, 51:1237-1243.
89. Stone MJ, Klintmalm GB, Polter D, et al. Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients. Gastroenterology 1993, 104:196-202.
90. Cherqui D, Piedbois P, Pierga JY, et al. Multimodal adjuvant treatment and liver transplantation for advanced hepatocellular carcinoma. A pilot study. Cancer 1994, 73:2721-2726.
91. Roayaie S, Frischer JS, Emre SH, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002, 235:533-539.
92. Hsieh CB, Chou SJ, Shih ML, et al. Preliminary experience with gemcitabine and cisplatin adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol 2008, 34:906-910.
93. Olthoff KM, Rosove MH, Shackleton CR, et al. Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Ann Surg 1995, 221:734-741.
94. Zhang ZH, Ma LW, Song SB, et al. Adjuvant chemotherapy after orthotopic liver transplantation for advanced hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 2005, 27:45-47. (in Chinese).
95. Chen GH, Lu MQ, Cai CJ, et al. Clinical study of adjuvant individualized chemotherapy for hepatocellular carcinoma after liver transplantation. Zhonghua Wai Ke Za Zhi 2004, 42:1040-1043. (in Chinese).
96. Sun J, Hou BH, Jian ZX, et al. Value of perioperative adjuvant therapy in liver transplantation for advanced hepatocellular carcinoma. Nan Fang Yi Ke Da Xue Xue Bao 2007, 27:471-473. (in Chinese).
97. Xu J, Shen ZY, Chen XG, et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 2007, 45:269-276.
98. Soderdahl G, Backman L, Isoniemi H, et al. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int 2006, 19:288-294.
99. Pokorny H, Gnant M, Rasoul-Rockenschaub S, et al. Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation?. Am J Transplant 2005, 5:788-794.
100. Li N, Zhou J, Weng D, et al. Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2007, 13:5847-5854.
101. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
102. Kita Y, Klintmalm G, Kobayashi S, et al. Retransplantation for de novo hepatocellular carcinoma in a liver allograft with recurrent hepatitis B cirrhosis 14 years after primary liver transplantation. Dig Dis Sci 2007, 52:392-393.
103. Taketomi A, Fukuhara T, Morita K, et al. Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation. Ann Surg Oncol 2010, 17:2283-2289.
104. Yoon DH, Ryoo BY, Ryu MH, et al. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol 2010, 40:768-773.